At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.54: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.09BUSDvs all stocks (USD)
Revenue (TTM)
275.59MUSDvs all stocks (USD)
Profit Margin
-13.51%Beta
0.1850xvs all stocks
52-Week Change
-24.14%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
1.09BUSDvs all stocks (USD)
Enterprise Value
1.28BUSDvs all stocks (USD)
Forward P/E
10.44xPrice to Sales (TTM)
3.94xPrice to Book (MRQ)
71.31xEnterprise to Revenue
4.65xEnterprise to EBITDA
72.32xGross Margin
71.27%Profit Margin
-13.51%Operating Margin
-15.58%Return on Assets (TTM)
-0.45%Return on Equity (TTM)
-116.07%Revenue (TTM)
275.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.40USDUpdated Oct 27, 2026Quarterly Revenue Growth
10.90%Gross Profit (TTM)
201.96MUSDvs all stocks (USD)
EBITDA (TTM)
50.24MUSDvs all stocks (USD)
Net Income (TTM)
-37.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.85%Operating Cash Flow (TTM)
6.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.49MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-355.00KUSDFY2025 · Dec 31, 2025Revenue
272.30MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
67.93MUSDFY2025 · Dec 31, 2025Gross Profit
204.37MUSDFY2025 · Dec 31, 2025Operating Income
30.52MUSDvs all stocks (USD)
Pre-tax Income
-1.37MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.77MUSDFY2025 · Dec 31, 2025Net Income
-5.14MUSDFY2025 · Dec 31, 2025EBIT
22.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
50.24MUSDFY2025 · Dec 31, 2025Research & Development
20.94MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
152.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
24.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
36.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
36.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-5.14MUSDFY2025 · Dec 31, 2025Operating Cash Flow
29.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
28.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
72.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
93.00KUSDFY2025 · Dec 31, 2025Interest Paid
18.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.05MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
5.01MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-4.61MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-887.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-215.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.36MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
244.38MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-230.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-26.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.19MUSDFY2025 · Dec 31, 2025Shares Outstanding
37.48MSharesUpdated Oct 27, 2026Float Shares
28.93MSharesUpdated Oct 27, 2026Shares Short
7.76MSharesUpdated Oct 27, 2026Short Ratio
13.98daysvs all stocks
Short % of Shares Outstanding
23.04%vs all stocks
% Held by Insiders
15.38%vs all stocks
% Held by Institutions
58.56%vs all stocks
Total Cash (MRQ)
85.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.28USDUpdated Oct 27, 2026Total Debt (MRQ)
300.74MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
20.26xCurrent Ratio (MRQ)
2.24xBook Value per Share (MRQ)
0.4060USDUpdated Oct 27, 2026Total Assets
399.48MUSDvs all stocks (USD)
Total Current Assets
211.75MUSDFY2025 · Dec 31, 2025Total Liabilities
347.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
187.73MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
251.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
96.30MUSDFY2025 · Dec 31, 2025Cash
72.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
72.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
110.89MUSDFY2025 · Dec 31, 2025Inventory
13.52MUSDFY2025 · Dec 31, 2025Accounts Payable
35.35MUSDFY2025 · Dec 31, 2025Short-term Debt
887.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
788.00KUSDFY2025 · Dec 31, 2025Long-term Debt
251.09MUSDFY2025 · Dec 31, 2025Common Stock (Book)
37.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-156.52MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
52.09MUSDvs all stocks (USD)
52-Week Low
26.96USDUpdated Oct 27, 202652-Week High
54.85USDUpdated Oct 27, 202652-Week Change
-24.14%vs all stocks
Beta
0.1850xvs all stocks
50-Day MA
34.00USDUpdated Oct 27, 2026200-Day MA
38.83USDUpdated Oct 27, 2026Avg 10-Day Volume
602.37KSharesUpdated Oct 27, 2026Avg 30-Day Volume
631.36KSharesUpdated Oct 27, 2026Diluted EPS (TTM)
-0.9900USDUpdated Oct 27, 2026Other Income / Expense
-7.70MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.14
Financial Health
Altman Z-Score 2.54: grey zoneSignificant
Altman Z-Score: 2.54
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule